NCT04918823View on ClinicalTrials.gov

Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

10

Participants

Timeline

Start Date

July 15, 2021

Primary Completion Date

April 4, 2023

Study Completion Date

April 14, 2023

Conditions

Ocular Surface Disease

Interventions

DRUG

Restasis

Subject will use one drop of Restasis in the lens before insertion

Trial Locations (1)

02494

BostonSight, Needham

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors

collaborator

Allergan

INDUSTRY

lead

Boston Sight

OTHER

NCT04918823 - Novel Use of Cyclosporine Ophthalmic Emulsion 0.05% in a PROSE Device | Biotech Hunter | Biotech Hunter